Why does enterprise-value logic fail for banks — and how do you actually value one?
An advanced Valuation question — expect it in final rounds and case-heavy interviews (IB, PE, Big-4 Transaction Services).
THE SHORT ANSWER
For a bank, debt is not financing but raw material: deposits and wholesale funding are the inputs the business earns its spread on, so separating 'operating' from 'financing' — the entire premise of enterprise value and EV/EBITDA — collapses. Interest is the core operating line, and capex-like concepts barely exist. You therefore value the equity directly: price-to-book and price-to-earnings against peers, a dividend discount model, or residual income (excess of ROE over cost of equity capitalized onto book value). The controlling relationship is the value triangle: P/B exceeds 1.0 exactly when sustainable ROE exceeds the cost of equity, and the spread times growth determines how far. Regulation is the constraint layer — CET1 requirements cap leverage and distributions, so any dividend-based valuation must respect the capital plan. Asset quality diligence (NPL coverage, stage 2/3 migration) is the banking equivalent of QoE: overstated book value corrupts every multiple built on it.
WHAT INTERVIEWERS LISTEN FOR
- ✓deposits are raw material — EV separation collapses
- ✓equity-side methods: P/B, P/E, DDM, residual income
- ✓P/B > 1 iff ROE > cost of equity
- ✓regulatory capital caps distributions — constrain the model
- ✓book value quality (NPLs, coverage) underpins all multiples
COMMON MISTAKES
- ✗using EV/EBITDA on a bank
- ✗ignoring capital requirements in dividend capacity
You've seen the model answer. Now get graded on yours.
In the interview you won't have this page — you deliver your version on a clock. Practice this and 1,000+ questions with AI feedback on every answer.
RELATED QUESTIONS
- How do you value a company with no revenue?
- Explain accretion/dilution analysis.
- How would you value a company in a cyclical industry?
- What is the most appropriate valuation methodology for a company with significant intangible assets but no current revenue, such as a biotech startup in the pre-clinical stage?
- When calculating WACC for a company with multiple divisions in different countries, what is the correct approach?
- How does a private equity buyer use an LBO to set the maximum price it can pay, and why is this a valuation floor?